FIGS, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FIGS research report →
Range $16 – $25
Price Chart
About the company
FIGS, Inc. functions as a direct-to-consumer enterprise specializing in healthcare apparel and lifestyle merchandise across the United States. The company innovates and distributes a comprehensive selection of medical uniforms, complemented by a diverse array of non-scrub items.
- CEO
- Catherine Eva Spear
- IPO
- 2021
- Employees
- 359
- HQ
- Santa Monica, CA, US
Get TickerSpark's AI analysis on FIGS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.33B
- P/E
- 46.41
- Fwd P/E
- 49.36
- PEG
- 0.15
- P/S
- 4.50
- P/B
- 7.47
- EV/EBITDA
- 33.62
- Div Yield
- 0.00%
- Gross Margin
- 68.33%
- Op Margin
- 10.78%
- Net Margin
- 9.67%
- ROE
- 16.45%
- ROIC
- 12.64%
Latest fiscal year · YoY change
- Revenue
- $631.10M+13.6%
- Gross Profit
- $419.84M+11.8%
- Op Income
- $38.15M
- Net Income
- $34.25M+1159.2%
- EPS
- $0.21+1204.3%
- OCF Growth
- -24.6%
- FCF Growth
- -17.4%
- 52W High
- $23.77
- 52W Low
- $4.98
- 50D MA
- $17.66
- 200D MA
- $14.15
- Beta
- 1.06
- RSI (14)
- 49
- Avg Volume
- 3.55M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FIGS posted another strong quarter with 26% revenue growth, margin expansion, and a raised full-year outlook, while management said momentum is broad-based despite supply constraints.· November 5, 2026
- Q3 net revenue rose 26% year over year to $190.7 million, with adjusted EBITDA margin up to 16.5% and diluted EPS of $0.10.
- Growth was broad-based: U.S. revenue increased 21%, international revenue jumped 51%, scrubwear grew 24%, and non-scrubwear grew 35%.
- Gross margin remained strong at 69.3%, though down 60 bps year over year; management cited pricing, mix, lower returns, and some offset from inventory reserves and supplier transition costs.
- Active customers increased 14% to nearly 3.2 million, average order value rose 11% to $126, and net revenue per active customer reached a record $236.
- Guidance was raised: Q4 revenue growth is expected at about 15%, full-year 2026 revenue growth at about 23.5%, and full-year adjusted EBITDA margin at about 15.8%.
FIGS reported Q3 2026 net revenue of $190.7 million, up 26% year over year; diluted EPS was $0.10 versus $0.05 last year; gross margin was 69.3%, down 60 basis points year over year; operating margin was 11.6% versus 6.4% last year; and adjusted EBITDA margin was 16.5% versus 12.4% last year. Active customers rose 14% to nearly 3.2 million, average order value increased 11% to $126, and net revenue per active customer increased 13% to a record $236. For Q4, management expects about 15% year-over-year revenue growth. For full-year 2026, management now expects net revenue growth of about 23.5%, full-year GAAP gross margin of about 69.9%, operating margin of about 12%, and adjusted EBITDA margin of about 15.8%.
Trina Spear framed the quarter as evidence that FIGS has moved into a new growth phase, saying performance was broad-based across product, channel, and geography. She emphasized stronger product execution, more effective brand marketing, improving customer quality, and the company’s ability to expand beyond scrubs into more of the healthcare workflow. Her tone was upbeat and confident, but she repeatedly noted that supply constraints and the Jordan-related transition are still limiting near-term sales capture.
Sarah Oughtred highlighted that Q3 revenue, profitability, and cash all exceeded expectations, with record cash and short-term investments of $331.2 million, inventory of $121.3 million, and $14 million of buybacks during the quarter at a weighted average price of $14.02. She said gross margin was 69.3%, down 60 bps but ahead of expectations, and noted operating margin improved to 11.6% and adjusted EBITDA margin to 16.5%. She also said the company has about $105 million remaining under its repurchase authorization, inventory should stay down year over year in Q4 before rebuilding in 2027, and the normalized gross margin rate this year would be in the 67.5-ish range.
Analysts focused on whether FIGS has entered a new sustainable growth algorithm, what the competitive opportunity is after Scrubs & Beyond’s store closures, and how much the Jordan supplier disruption and stockouts are suppressing sales. Management said growth is being driven by multiple vectors, including U.S. e-commerce, international, TEAMS, and Community Hubs, and pointed to strong leading indicators such as traffic, search, social following, and email/SMS growth. On stockouts, Sarah said the quarter could have been stronger with better inventory supply, but it is hard to quantify precisely; she expects some impact into Q1, with the worst of the Jordan-related effect in Q4 and continuing into Q2 next year. They also said TEAMS sales cycles are getting shorter, buybacks are being used to offset dilution, and international growth is still mostly coming from existing markets rather than new market launches.
The bull case from this call is that FIGS is sustaining unusually strong demand while also expanding profitability, with four straight quarters of more than 25% growth and improving margins. Management also sees multiple long-term growth levers still early: international expansion, TEAMS, Community Hubs, non-scrubs, and more product innovation. Leading indicators such as traffic, search, and subscriber growth suggest momentum may continue into 2027.
The main risks discussed were supply constraints, including the Jordan-related transition and stockouts, which management said limited sales in Q3 and could continue into Q1 and Q2 next year. Gross margin also faces moving pieces from tariff refunds, freight, and the Vietnam transition, and management said some of this year’s margin benefit is one-time. Competition and market penetration also remain open questions, since FIGS still has relatively low brand awareness globally and much of international growth is still coming from existing markets rather than brand-new ones.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.7%
- Shares Outstanding
- 165.77M
- Float Shares
- 150.33M
of shares held by institutions
255 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bamco Inc | 59.96M | 0 |
| Vanguard Group Inc | 9.61M | ▲ 201 |
| Blackrock, Inc. | 8.72M | ▲ 179.89K |
| Driehaus Capital Management LLC | 5.16M | ▲ 986.98K |
| Vanguard Capital Management LLC | 4.63M | ▼ 41.29K |
| Vanguard Portfolio Management LLC | 4.18M | ▼ 209.55K |
| Goldman Sachs Group Inc | 3.69M | ▲ 1.33M |
| Dimensional Fund Advisors LP | 3.46M | ▼ 108.76K |
| Divisadero Street Capital Management, LP | 3.19M | ▼ 5.37K |
| Marshall Wace, Llp | 3.18M | ▼ 1.15M |
| Geode Capital Management, LLC | 3.10M | ▼ 540.04K |
| Arrowstreet Capital, Limited Partnership | 3.02M | ▼ 721.72K |
Held by 266 ETFs
Biggest fund positions in FIGS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Marte Mario Jesus | other | 7,500 |
| Nov 11, 26 | Oughtred Sarah | sell | 90,000 |
| Nov 9, 26 | Spear Catherine Eva | other | 900,000 |
| Nov 9, 26 | Spear Catherine Eva | other | 7,695,000 |
| Nov 9, 26 | Spear Catherine Eva | other | 4,550,716 |
| Nov 9, 26 | Spear Catherine Eva | sell | 4,044,284 |
| Nov 9, 26 | Spear Catherine Eva | other | 7,695,000 |
| Nov 9, 26 | Spear Catherine Eva | other | 900,000 |
| Nov 2, 26 | Hasson Heather L. | other | 30,141 |
| Nov 2, 26 | Oughtred Sarah | other | 21,962 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FIGS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on FIGS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Figs Stock Popped Today
fool.com · Nov 18
Noah Wyle and FIGS Partner Together to Relieve At Least $200 Million of Medical Debt Nationwide
businesswire.com · Nov 17
Figs (FIGS) is a Great Momentum Stock: Should You Buy?
zacks.com · Nov 17
Why Figs (FIGS) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 17
Alps Advisors Inc. Buys New Position in FIGS, Inc. $FIGS
defenseworld.net · Nov 14
Earnings Estimates Rising for Figs (FIGS): Will It Gain?
zacks.com · Nov 9
Why Figs Stock Popped Today
fool.com · Nov 9
FIGS: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
